CA2266325A1 - A family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof - Google Patents

A family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof

Info

Publication number
CA2266325A1
CA2266325A1 CA002266325A CA2266325A CA2266325A1 CA 2266325 A1 CA2266325 A1 CA 2266325A1 CA 002266325 A CA002266325 A CA 002266325A CA 2266325 A CA2266325 A CA 2266325A CA 2266325 A1 CA2266325 A1 CA 2266325A1
Authority
CA
Canada
Prior art keywords
sarp
cancer
protein
test sample
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002266325A
Other languages
French (fr)
Other versions
CA2266325C (en
Inventor
Samuil Umansky
Hovsep Melkonyan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26701439&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2266325(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of CA2266325A1 publication Critical patent/CA2266325A1/en
Application granted granted Critical
Publication of CA2266325C publication Critical patent/CA2266325C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

An isolated polynucleotide at leat 60 % homologous to SEQ ID NO: 1, 3, 5 or 18 encoding a SARP polypeptide; vectors comprising a polynucleotide sequence encoding at least 11 consecutive amino acids of .alpha.SARP polypeptide; a host cell transformed with an isolated polynucleotide or vector; antibodies specific for SARP and use of such polynucleotides and antibodies in diagnostic and therapeutic method. Therapeutic uses of antibodies and polynucleotides of sarp. Methods for treating diseases related to the regulation of SARP expression in tissue and bodily fluid samples, including cancers.

Claims (44)

1. An isolated polynucleotide encoding a polypeptide having at least 90%
identity to SEQ ID NO: 2, 4, 6 or 7.
2. An isolated polynucleotide at least 15 nucleotides in length from the coding region of SEQ ID NO: 1, 3, 5 or 18, or complement thereof.
3. An isolated polypeptide encoded by the polynucleotide of claim 1.
4. An isolated polypeptide fragment or functionally equivalent polypeptide fragment to a sequence shown in SEQ ID NO: 2, 4, 6 or 7.
5. A fusion polypeptide comprising (1) a linear sequence of at last 11 amino acid residues essentially identical to a sequence shown in SEQ ID NO: 2, 4,
6 or 7, covalently attached to (2) a second polypeptide.

6. A recombinant expression vector comprising a polynucleotide sequence encoding a polypeptide of at least 11 consecutive amino acid residues shown in SEQ ID NO: 2, 4, 6 or 7.
7. A recombinant cloning vector comprising a linear sequence of at least 18 nucleotides identical to a linear sequence within SEQ ID NO: 1, 3, 5 or 18.
8. A host cell transformed by the polynucleotide of claim 1, or by the vector of claim 7.
9. The host cell of claim 8 wherein the cell expresses said polypeptide from said vector.
10. A monoclonal or isolated polyclonal antibody specific for a protein encoded in coding region of the polynucleotides of claim 1.
11. The antibody of claim 10, which is a monoclonal antibody.
12. The antibody of claim 10, which is an isolated polyclonal antibody.
13. A method of detecting SARP protein expression comprising the steps of:
(a) providing a test cell;
(b) contacting the proteins of the test cell with the antibody of claim 10 under conditions that permit formation of a stable complex between the proteins of the test cell and the antibody; and (c) comparing the amount of immunocomplex formed with the proteins of the test cell to the amount of immunocomplex formed with the proteins of a non-apoptotic cell of the same tissue type as the test cell.
14. A method of detecting SARP protein expression comprising the steps of:
(a) providing a test cell;
(b) contacting the mRNA of the test cell with a nucleic acid probe containing a sequence antisense to a segment at least 15 nucleotides in length of SEQ ID NO: 1, 3, 5 or 18 under conditions that permit formation of a stable complex between the mRNA of the test cell and the nucleic acid probe; and (c) comparing the amount of hybridization of the probe to the mRNA of the test cell to the amount of hybridization of the probe to the mRNA ofa non-apoptotic cell of the same tissue type as the test cell.
15. A method of diagnosing a disease associated with the modulation of SARP expression, comprising:
(a) providing a test sample of tissue;
(b) assaying said test sample for the presence of a gene product of an hsarp gene; and (c) comparing the amount of gene product detected in said test sample to the amount of gene product detected in a non-diseased sample of the same tissue type as the test sample.
16. The method of claim 15, wherein said gene product is a protein.
17. The method of claim 16, wherein assaying comprises contacting said test sample with an antibody to said protein under conditions that permit formation of a stable complex between said antibody and any of said protein present in said test sample.
18. The method of claim 15, wherein said gene product is an hsarp mRNA.
19. The method of claim 18, wherein assaying comprises contacting said test sample with a nucleic acid probe containing a sequence antisense to a segment at least 15 nucleotides in length of an hsarp mRNA under conditions that permit formation of a stable complex between the nucleic acid probe and any complementary mRNA present in said test sample.
20. The method of claim 15, wherein said hsarp gene is hsarp1.
21. The method of claim 20, wherein said disease is a cancer of the prostate epithelial tissue.
22. The method of claim 15, wherein said hsarp gene is hsarp2.
23. The method of claim 22, wherein said disease is a cancer of the mammary tissue.
24. A method of diagnosing a disease associated with the modulation of SARP expression, comprising:
(a) providing a test sample of bodily fluid;
(b) assaying said test sample for the presence of a SARP protein;
and (c) comparing the amount of SARP protein detected in said test sample to the amount of SARP protein detected in a non-diseased sample of the same fluid type as the test sample.
25. The method of claim 24, wherein assaying comprises contacting said test sample with an antibody to said SARP protein under conditions that permit formation of a stable complex between said antibody and any of said SARP
protein present in said test sample.
26. The method of claim 24, wherein said SARP protein is hSARP1.
27. The method of claim 26, wherein said disease is a cancer of the prostate epithelial tissue.
28. The method of claim 24, wherein said SARP protein is hSARP2.
29. The method of claim 28, wherein said disease is a cancer of the mammary tissue.
30. A method of treatment of a patient comprising administering to the patient a therapeutically effective amount of a pharmaceutically acceptable composition comprising a component selected from the group comprising a sarp or antisense-hsarp polynucleotide or a SARP polypeptide or SARP antibody.
31. The method of claim 30, wherein the patient is suffering from a condition related to cancer.
32. The method of claim 31, wherein the condition related to cancer is cancer of the mammary tissue.
33. The method of claim 31, wherein the condition related to cancer is cancer of the prostate.
34. The method of claim 31, wherein said condition related to cancer is a cancer of the prostate epithelial tissue.
35. The method of claim 30, wherein said polynucleotide is hsarp2.
36. The method of claim 30, wherein said polypeptide is SARP2
37. A method of treating an apoptosis related condition comprising administering a therapeutically effective amount of a pharmaceutically acceptable composition comprising a sarp or antisense-hsarp polynucleotide or a SARP
polypeptide or SARP antibody, to a patient in need of such therapy.
38. The method of claim 37, wherein said apoptosis related condition is a cancer.
39. The method of claim 38, wherein said cancer is cancer of the mammary tissue.
40. The method of claim 38, wherein said cancer is cancer of the prostate.
41. The method of claim 37, wherein said apoptosis related condition is a cancer of the prostate epithelial tissue.
42. The method of claim 37, wherein said polynucleotide is hsarp2.
43. The method of claim 37, wherein said polypeptide is SARP2.
44. A method for screening potential therapeutic agents that modulate the effect of SARP proteins on the Wnt-frizzled protein interaction comprising the steps of:
(a) combining a Wnt protein and a SARP protein under conditions in which they interact, to form a test sample;
(b) exposing said test sample to a potential therapeutic agent and;
(c) monitoring the interaction of the SARP protein and the frizzled protein. wherein, a potential therapeutic agent is selected for further study when it modifies the interaction compared to a control test sample to which no potentialtherapeutic agent has been added.
CA2266325A 1996-09-24 1997-09-24 A family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof Expired - Lifetime CA2266325C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US2660396P 1996-09-24 1996-09-24
US60/026,603 1996-09-24
US2836396P 1996-10-11 1996-10-11
US60/028,363 1996-10-11
PCT/US1997/017154 WO1998013493A2 (en) 1996-09-24 1997-09-24 A family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof

Publications (2)

Publication Number Publication Date
CA2266325A1 true CA2266325A1 (en) 1998-04-02
CA2266325C CA2266325C (en) 2012-07-17

Family

ID=26701439

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2266325A Expired - Lifetime CA2266325C (en) 1996-09-24 1997-09-24 A family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof

Country Status (11)

Country Link
US (3) US6433155B1 (en)
EP (1) EP0932678B2 (en)
JP (2) JP4299886B2 (en)
AT (1) ATE318915T1 (en)
AU (1) AU737323B2 (en)
CA (1) CA2266325C (en)
DE (1) DE69735375T3 (en)
DK (1) DK0932678T4 (en)
ES (1) ES2263181T5 (en)
PT (1) PT932678E (en)
WO (1) WO1998013493A2 (en)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070299005A1 (en) * 1996-09-24 2007-12-27 Tanox, Inc. Family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof
WO1998035043A1 (en) 1997-02-06 1998-08-13 Genetics Institute, Inc. Human sdf-5 protein and compositions
CA2224473A1 (en) * 1997-05-21 1998-11-21 Smithkline Beecham Corporation A novel human gene similar to a secreted murine protein sdf5
EP0879885A1 (en) * 1997-05-23 1998-11-25 Smithkline Beecham Corporation A novel human gene similar to a secreted murine protein sFRP-1
WO1998054325A1 (en) * 1997-05-29 1998-12-03 The Government Of The United States Of America,Re Presented By The Secretary, Department Of Health And Human Services Human frp and fragments thereof including methods for using them
US20030203446A1 (en) * 1998-10-07 2003-10-30 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
KR20010087383A (en) * 1998-10-30 2001-09-15 추후제출 Trans-species transfer of apoptotic genes and transgenic plants developed thereby
GB9921009D0 (en) * 1999-09-07 1999-11-10 Neuropa Ltd Essential genes and assays relating thereto
US20080166356A9 (en) * 1999-09-13 2008-07-10 Peter Bodine Pharmaceutical compositions and methods of using secreted frizzled related protein
US6600018B1 (en) 2000-04-10 2003-07-29 The United States Of America As Represented By The Department Of Health And Human Services Secreted frizzled related protein, sFRP, fragments and methods of use thereof
KR100804885B1 (en) 2000-12-06 2008-02-20 라보라토리스 세로노 에스.에이. Use of sarp-1 for treatment and/or prevention of scleroderma
CA2434672C (en) 2001-01-10 2014-03-25 Jeffrey S. Rubin Sfrp and peptide motifs that interact with sfrp and methods of their use
EP1222933A1 (en) * 2001-01-15 2002-07-17 Academisch Ziekenhuis Leiden h.o.d.n., Leids Universitair Medisch Centrum Generation and/or reduction of new lung tissue in an affected lung, by modulation of the Wnt-pathway
US20030044409A1 (en) * 2001-05-01 2003-03-06 Carson Dennis A. Immunologic compositions and methods for studying and treating cancers expressing frizzled antigens
AU2002308557A1 (en) * 2001-05-01 2002-11-11 The Regents Of The University Of California Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas
WO2004011618A2 (en) * 2002-07-29 2004-02-05 Hmgene, Inc. Methods of identifying adipocyte specific genes, the genes identified, and their uses
US20050054599A1 (en) * 2003-05-02 2005-03-10 Coles John G. Biosynthetic platform for cardioprotective stress response in human fetal heart tissue
CA2549796A1 (en) * 2003-12-16 2005-07-07 Aventis Pharmaceuticals Inc. Secreted neural apoptosis inhibiting proteins
CN114250299A (en) 2004-07-23 2022-03-29 太平洋边缘有限公司 Urine markers for detection of bladder cancer
ATE497389T1 (en) * 2005-08-19 2011-02-15 Univ Duke PARACCRINE FACTOR H12 OBTAINED FROM STEM CELLS FOR USE IN REDUCING CELL DEATH OR FOR REPAIR OF TISSUE
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
JP2009513708A (en) * 2005-10-31 2009-04-02 オンコメッド ファーマシューティカルズ インコーポレイテッド Compositions and methods for diagnosis and treatment of cancer
NZ545243A (en) * 2006-02-10 2009-07-31 Pacific Edge Biotechnology Ltd Urine gene expression ratios for detection of cancer
CA2662041A1 (en) * 2006-09-08 2008-03-13 Genentech, Inc. Wnt antagonists and their use in the diagnosis and treatment of wnt-mediated disorders
AU2009296246B2 (en) 2008-09-26 2015-07-30 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
TWI535445B (en) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Wnt antagonists and methods of treatment and screening
CN102971337B (en) 2010-04-01 2016-09-21 昂考梅德药品有限公司 FZ combines medicament and application thereof
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
US20120237975A1 (en) 2010-10-01 2012-09-20 Jason Schrum Engineered nucleic acids and methods of use thereof
EP2691101A2 (en) 2011-03-31 2014-02-05 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CA2850624A1 (en) 2011-10-03 2013-04-11 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
KR20140102759A (en) 2011-12-16 2014-08-22 모더나 세라퓨틱스, 인코포레이티드 Modified nucleoside, nucleotide, and nucleic acid compositions
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
CA2868398A1 (en) 2012-04-02 2013-10-10 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
CA2887711A1 (en) 2012-10-23 2014-05-01 Oncomed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using wnt pathway-binding agents
JP6144355B2 (en) 2012-11-26 2017-06-07 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． Chemically modified mRNA
CN105073195A (en) 2013-02-04 2015-11-18 昂科梅德制药有限公司 Methods and monitoring of treatment with a Wnt pathway inhibitor
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
JP2016538829A (en) 2013-10-03 2016-12-15 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Polynucleotide encoding low density lipoprotein receptor

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (en) 1970-11-10 1977-09-15 Organon Nv PROCEDURE FOR DETERMINING AND DETERMINING LOW MOLECULAR COMPOUNDS AND PROTEINS THAT CAN SPECIFICALLY BIND THESE COMPOUNDS AND TEST PACKAGING.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
AU2515992A (en) 1991-08-20 1993-03-16 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US5639856A (en) * 1993-09-13 1997-06-17 The Regents Of The University Of California Semaphorin gene family
US5663070A (en) 1993-11-15 1997-09-02 Lxr Biotechnology Inc. Recombinant production of a soluble splice variant of the Fas (Apo-1) antigen, fas TM
US5759548A (en) 1993-11-30 1998-06-02 Lxr Biotechnology Inc. Compositions which inhibit apoptosis, methods of purifying the compositions and uses thereof
US5672686A (en) 1994-08-09 1997-09-30 Immunogen, Inc. Bcl-Y - specific antibodies

Also Published As

Publication number Publication date
AU4651397A (en) 1998-04-17
DE69735375T2 (en) 2006-11-30
DE69735375T3 (en) 2010-09-02
ES2263181T3 (en) 2006-12-01
PT932678E (en) 2006-07-31
WO1998013493A2 (en) 1998-04-02
AU737323B2 (en) 2001-08-16
WO1998013493A3 (en) 1998-06-04
US7045604B2 (en) 2006-05-16
DK0932678T3 (en) 2006-05-22
ATE318915T1 (en) 2006-03-15
US6433155B1 (en) 2002-08-13
JP2009050257A (en) 2009-03-12
CA2266325C (en) 2012-07-17
US7045596B2 (en) 2006-05-16
JP2002516564A (en) 2002-06-04
US20040039184A1 (en) 2004-02-26
US20030023061A1 (en) 2003-01-30
EP0932678B2 (en) 2010-03-10
DK0932678T4 (en) 2010-07-12
ES2263181T5 (en) 2011-04-07
DE69735375D1 (en) 2006-04-27
JP4299886B2 (en) 2009-07-22
EP0932678A2 (en) 1999-08-04
EP0932678B1 (en) 2006-03-01

Similar Documents

Publication Publication Date Title
CA2266325A1 (en) A family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof
EP1493033B1 (en) Use of sc6 for diagnosis and treatment of breast carcinoma
JP3387745B2 (en) MET proto-oncogene as liver growth factor receptor
CA2133306C (en) Amplification of human mdm2 gene in human tumors
Sánchez et al. Identification of the major protein components in breast secretions from women with benign and malignant breast diseases
US6218131B1 (en) Materials and methods for detection of breast cancer
CA2395699A1 (en) Nucleic acids, proteins, and antibodies
Heider et al. Splice variants of the cell surface glycoprotein CD44 associated with metastatic tumour cells are expressed in normal tissues of humans and cynomolgus monkeys
HUP9800784A2 (en) Angiostatin fragments and aggregate angiostatin and methods of use
US7744882B2 (en) Soluble ErbB3 methods of detection and antibodies
JP2005510734A (en) Diagnosis and treatment method of epithelial induced cancer
KR20160133740A (en) Composition for diagnosing or prognosising cancer comprising fibronectin protein positive exosome
EP2158327B1 (en) Cancer related isoforms of components of transcription factor complexes as biomarkers and drug targets
EP3519592B1 (en) Materials and methods for evaluating cancer
WO2003010205A1 (en) Genes induced by hypoxia
US6475775B1 (en) PARG, a GTPase activating protein which interacts with PTPL1
JP2002518016A5 (en)
RU2307666C2 (en) Polynucleotide modulating cancer cell proliferation (variants), polypeptide, monoclonal antibody, expression vector, host cell, pharmaceutical agent for treatment of proliferative disease, pharmaceutical composition, polypeptide uses in pharmaceutical agent production
US20230250149A1 (en) Antigen-specific t cell receptors and chimeric antigen receptors, and methods of use in immune signaling modulation for cancer immunotherapy
EP1796723B1 (en) Method of diagnosing cancer by detecting the expression of spag9 or the presence of anti-spag9 antibodies
WO2002030974A2 (en) Proteins and nucleic acids encoding same
WO2001064879A2 (en) G-proteins coupled receptor related polypeptides
KR102499678B1 (en) A Composition for Diagnosing Cancer
KR102280360B1 (en) A Composition for Diagnosing Cancer
US20040005645A1 (en) Protein markers for esophageal cancer

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20170925